Sustained Clinical Remission With Vedolizumab in Patients With Moderate-to-Severe Ulcerative Colitis

Feagan, Brian G.; Schreiber, Stefan; Wolf, Douglas C.; Axler, Jeffrey; Kaviya, Arpeat; James, Alexandra; Curtis, Rebecca; Geransar, Parnia; Stallmach, Andreas; Ehehalt, Robert; Bokemeyer, Bernd; Khalid, Javaria Mona; O’Byrne, Sharon

doi:10.1093/ibd/izy323

Cited by 26 publications

(18 citation statements)

References 27 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The ‘Intestinal immune network for IgA production’ signaling pathway is associated with inflammatory immune diseases, including kidney diseases and osteoarthritis ( 40 , 41 ), and is emerging as a novel target of potential therapeutic interventions ( 42 ). As an important metabolic pathway, the activation of the ‘cAMP signaling pathway’ has also been reported to inhibit proliferation of glioma ( 43 , 44 ).…”

Section: Discussionmentioning

confidence: 99%

Development of a prognostic model of glioma based on immune‑related genes

Wang¹,

Wang²,

Zhu³

et al. 2020

Oncol Lett

View full text Add to dashboard Cite

Glioma is the most common type of primary brain cancer, and the prognosis of most patients with glioma, and particularly that of patients with glioblastoma, is poor. Tumor immunity serves an important role in the development of glioma. However, immunotherapy for glioma has not been completely successful, and thus, comprehensive examination of the immune-related genes (IRGs) of glioma is required. In the present study, differentially expressed genes (DEGs) and differentially expressed IRGs (DEIRGs) were identified using the edgeR package. Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway analysis was used for functional enrichment analysis of DEIRGs. Survival-associated IRGs were selected via univariate Cox regression analysis. A The Cancer Genome Atlas prognostic model and GSE43378 validation model were established using lasso-penalized Cox regression analysis. Based on the median risk score value, patients were divided into high-risk and low-risk groups for clinical analysis. Receiver operating characteristic curve and nomogram analyses were used to assess the accuracy of the models. Reverse transcription-quantitative PCR was performed to measure the expression levels of relevant genes, such as cyclin-dependent kinase 4 (CDK4), interleukin 24 (IL24), NADPH oxidase 4 (NOX4), bone morphogenetic protein 2 (BMP2) and baculoviral IAP repeat containing 5 (BIRC5). A total of 3,238 DEGs, including 1,950 upregulated and 1,288 downregulated DEGs, and 97 DEIRGs, including 60 upregulated and 37 downregulated DEIRGs, were identified. ‘Neuroactive ligand-receptor interaction’ and ‘Cytokine-cytokine receptor interaction’ were the most significantly enriched pathways according to KEGG pathway analysis. A prognostic model and a validation prognostic model were created for glioma, including 15 survival-associated IRGs (FCER1G, NOX4, TRIM5, SOCS1, APOBEC3C, BIRC5, VIM, TNC, BMP2, CMTM3, IL24, JAG1, CALCRL, HNF4G and CDK4). Furthermore, multivariate Cox regression analysis results suggested that age, high WHO Grade by histopathology, wild type isocitrate dehydrogenase 1 and high risk score were independently associated with poor overall survival. The infiltration of B cells, CD8 + T cells, dendritic cells, macrophages and neutrophils was positively associated with the prognostic risk score. In the present study, several clinically significant survival-associated IRGs were identified, and a prognosis evaluation model of glioma was established.

show abstract

Section: Discussionmentioning

confidence: 99%

Development of a prognostic model of glioma based on immune‑related genes

Wang¹,

Wang²,

Zhu³

et al. 2020

Oncol Lett

View full text Add to dashboard Cite

show abstract

“…Los análisis post hoc de los datos de GEMINI indicaron mayores tasas de remisión a los 12 meses en pacientes sin tratamiento previo con anti-TNF-α en comparación con los fracasos de la terapia anti-TNF-α 25 . Varios estudios han demostrado mejores resultados con VDZ en pacientes sin tratamiento previo con anti-TNF-α vs. pacientes tratados con anti-TNF-α [26][27][28][29][30] . Los resultados del estudio actual son consistentes con estos hallazgos.…”

Section: Discussionunclassified

Vedolizumab como terapia primaria en colitis ulcerosa y en la enfermedad de Crohn de moderada a grave: revisión y metaanálisis

Vaca¹,

Cortés-Espinoza²,

Maldonado-Arriaga³

et al. 2023

IMIDS

View full text Add to dashboard Cite

La colitis ulcerosa (CU) y la enfermedad de Crohn (EC) tienen diferentes opciones de tratamiento, que incluyen aminosalicilatos, corticosteroides, tiopurinas, inhibidores de calcineurina y biológicos como anticitocinas y antiintegrinas. Y recientemente el uso de vedolizumab (VDZ), el cual es un anticuerpo monoclonal humanizado selectivo para el intestino que se une a las integrinas α4β7, bloqueando selectivamente el tráfico de linfocitos en el intestino. El objetivo de este metaanálisis fue estimar la eficacia y seguridad del fármaco VDZ en ensayos clínicos aleatorizados en pacientes adultos no tratados previamente con terapia biológica y corticosteroides con CU y EC. Metodología: Se realizó una revisión sistemática de la literatura y un metaanálisis para evaluar la efectividad y seguridad del VDZ en pacientes con CU y EC. Se realizó una búsqueda en las bases de datos PubMed/Medline sobre pacientes adultos con CU sin previo uso de terapia biológica y corticosteroides bajo tratamiento de VDZ en ensayos clínicos aleatorizados. Resultados: Se seleccionaron cinco estudios que cumplieron los criterios de selección. Y se determinó que en la semana 14 de tratamiento, el 32% de los pacientes con CU estaban en remisión; y a los 12 meses, el 46% estaba en remisión clínica. Las tasas de remisión sin corticosteroides fueron del 26% en la semana 14 y del 42% en el mes 12. En el mes 12, del 33 al 77% de los pacientes con CU presentaron curación de la mucosa. El 9% de los pacientes informaron eventos adversos graves. Conclusiones: El VDZ demostró eficacia en pacientes con CU y EC activa de moderada a grave, logrando la remisión en el mes 12 de tratamiento. Estos hallazgos concuerdan con los datos y el apoyo de los ensayos clínicos aleatorizados muestran el perfil de riesgo-beneficio a largo plazo del VDZ.

show abstract

“…Clinical remission was defined as a partial Mayo score (PMS) of 2 or less with a rectal bleeding subscore of 0 and no subscore > 1. Patients were considered to have a relapse when they no longer satisfy the definition of clinical remission (PMS > 2 or rectal bleeding score > 0) 19 . The relapse rate within a year after CCE2 was retrospectively analyzed according to the medical records as a primary outcome.…”

Section: Methodsmentioning

confidence: 99%

“…Patients were considered to have a relapse when they no longer satisfy the definition of clinical remission (PMS > 2 or rectal bleeding score > 0). 19 The relapse rate within a year after CCE2 was retrospectively analyzed according to the medical records as a primary outcome.…”

Section: Methodsmentioning

confidence: 99%

Determining the usefulness of Capsule Scoring of Ulcerative Colitis in predicting relapse of inactive ulcerative colitis

Matsubayashi

Okabayashi

Nakano

et al. 2020

J of Gastro and Hepatol

View full text Add to dashboard Cite

Background and Aim: The usefulness of second-generation colon capsule endoscopy (CCE2) in ulcerative colitis (UC), especially in clinically inactive patients, has been reported. Capsule Scoring of Ulcerative Colitis (CSUC) was developed as a severity index for UC. We aimed to determine whether CSUC is useful for predicting relapse during clinical remission. Methods: Forty-one UC patients in clinical remission who underwent CCE2 were prospectively registered from April 2016 to August 2019. Patients' CSUC score was obtained; those with subsequent relapse were followed up retrospectively. The correlation of CSUC with white blood cell count, platelet count, albumin, C-reactive protein, fecal calprotectin and fecal lactoferrin levels, and fecal immunochemical test results was evaluated; their predictive values for future relapse were compared. Results: The correlations of CSUC with white blood cell, platelet, albumin, C-reactive protein, fecal calprotectin, fecal immunochemical test, and fecal lactoferrin values were r s = 0.13, 0.27, À0.25, 0.15, 0.50, 0.43, and 0.50, respectively. CSUC was higher in 12 patients who relapsed within 1 year than in 29 patients who remained in clinical remission (2.83 ± 1.95 vs 0.72 ± 1.00, P < 0.01). Receiver operator characteristic curve analysis showed that CSUC ≥ 1 was a predictor of relapse (area under the curve of 0.82, sensitivity of 83.3%, specificity of 58.6%) and maybe superior to fecal biomarkers. In the univariate analysis, patients with CSUC of 0 had a lower relapse rate than those with CSUC of ≧ 1 (P = 0.03, log-rank test). After analyzing patients who underwent CCE2 within 6 months after the successful induction treatment, results showed that those with CSUC of ≤ 1 remained in clinical remission for a year. Conclusion: CSUC predicts relapse within 1 year in UC patients in clinical remission, especially when used 6 months after induction treatment.

show abstract

Sustained Clinical Remission With Vedolizumab in Patients With Moderate-to-Severe Ulcerative Colitis

Cited by 26 publications

References 27 publications

Development of a prognostic model of glioma based on immune‑related genes

Development of a prognostic model of glioma based on immune‑related genes

Vedolizumab como terapia primaria en colitis ulcerosa y en la enfermedad de Crohn de moderada a grave: revisión y metaanálisis

Determining the usefulness of Capsule Scoring of Ulcerative Colitis in predicting relapse of inactive ulcerative colitis

Contact Info

Product

Resources

About